No real transactions

Z-rostudirsen

Research only

Duchenne muscular dystrophy amenable to exon 51 skipping

Search PubMedNCT05524883Publications

Published evidence

1 publications0 exact-program1 related1 context / correction notes

Review publications

Program details

Sponsor describes a PMO conjugated to an antibody fragment and a January 21, 2027 FDA target.

Program names
zeleciment rostudirsen / z-rostudirsen / DYNE-251
Modality
ASO / siRNA
Indication
Duchenne muscular dystrophy amenable to exon 51 skipping
Associated trial
NCT05524883
FDA target
January 21, 2027Date-only guidance; not a trading cutoff.

Publications 1

Evidence is grouped by its relationship to this program.

Search PubMed

Publication notes explain the evidence behind this program. PubMed / NCBI data notice

Coverage & interpretation
  • Only a broad review was identified by the bounded program-name query; no primary DELIVER clinical-results paper is included.
  • Fab-PMO identity comes from the verified sponsor/registry record, not a generic antibody assumption.

No exact-program publication is linked here yet. Follow the registry and PubMed sources to explore further.

Same compound & related evidence

1 record
Related evidencereviewPMID 41560619

Antibodies to watch in 2026.

mAbs · 2026-01-21

This annual review surveys antibody therapeutics in development, review and approval. It includes zeleciment rostudirsen among antibody-oligonucleotide conjugates, but does not provide a primary human efficacy analysis for the DYN program.

Program relevance

A broad antibody-development review names zeleciment rostudirsen among antibody-oligonucleotide conjugates; it is not a DELIVER results paper.

Formulation / population: Zeleciment rostudirsen is a Fab-PMO conjugate; this broad review does not make it antibody monotherapy.

  • Broad review, not primary DELIVER clinical results.

Journal Article / Review

PubMedPublisher / DOIFull text

Sources

Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.

sponsor-releaseinvestors.dyne-tx.com
Sponsor describes a PMO conjugated to an antibody fragment and a January 21, 2027 FDA target.
Published
Jul 20, 2026
Retrieved
2026-10-30 02:09:48 UTC
sponsor-clinical-trialswww.dyne-tx.com
Sponsor links the DELIVER study of DYNE-251 to NCT05524883.
Published
Not supplied
Retrieved
2026-10-30 02:09:48 UTC
clinical-trial-registryclinicaltrials.gov
Registry identifies the associated compound, condition and sponsor; trial completion is separate from FDA action.
Published
Not supplied
Retrieved
2026-10-30 02:09:48 UTC

Research identity and publications do not establish regulatory approval, clinical suitability or an executable market. Read the limits